Abstract 240P
Background
Cervical cancer is one of the leading causes of morbidity and mortality among women from cancer of the reproductive organs in developing countries. The purpose of this study is to analyze the dynamics of morbidity and mortality from cervical cancer in the Republic of Kazakhstan.
Methods
Mortality and morbidity rates were calculated for the period 2007-2016. 95% confidence intervals are presented. Incidence of and mortality rates were calculated per 100,000 (0/0000) of female population. All statistical calculations were performed using SPSS (Statistical Package for the Social Sciences) software, version 20.0 for Windows.
Results
For the period from 2007 to 2016, the incidence rates of cervical cancer were analyzed, which varied from 15.24 to 18.83 per 100,000 of female population. Mortality rates tended to decline over the 10-year period under review in 2007, reaching 7.8 to 7.0 per 100,000 of female population in 2016. There is a difference in morbidity and mortality from cervical cancer between different regions of Kazakhstan. An analysis of the distribution of the incidence in the Republic of Kazakhstan revealed the highest incidence rates in the northern region of the country 28.2 (95% CI: 23.6-33.5) and the north-eastern region 27.3 (95% CI: 22.4-32.9) per 100,000 of female population. On the other hand, the lowest morbidity and mortality rates were found in the southern region substituted 10.4 (95% CI: 7.4-14.2) and 5.4 (95% CI: 4.3-6.8) per 100,000 of female population respectively.
Conclusions
Thus, the incidence of cervical cancer in the Republic of Kazakhstan has increased over the 10-year period in question, while mortality rates have been gradually decreasing. Such trends can result from the national screening program which was implemented in Kazakhstan.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract